Difference between revisions of "Cancer drugs"

From Libre Pathology
Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 18: Line 18:
| Herceptin
| Herceptin
| 3345 Euros/month<ref name=spiegel8_8_11_124/>
| 3345 Euros/month<ref name=spiegel8_8_11_124/>
| breast cancer, stomach cancer
| [[breast cancer]], stomach cancer
| notes?
| notes?
|-
|-
Line 24: Line 24:
| Iressa
| Iressa
| 3496 Euros/month<ref name=spiegel8_8_11_124/>
| 3496 Euros/month<ref name=spiegel8_8_11_124/>
| [[Lung cancer]]
| [[lung cancer]]
| EGFR inhibitor - like erlotinib
| [[EGFR inhibitor]] - like erlotinib
|-
|-
| panitumumab
| panitumumab
| Vectibix
| Vectibix
| 3537 Euros/month<ref name=spiegel8_8_11_124/>
| 3537 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| indication ???
| notes?
| notes?
|-
|-
Line 42: Line 42:
| Femara
| Femara
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| indication ???
| non-steroidal aromatase inhibitor
| non-steroidal aromatase inhibitor
|-
|-
Line 48: Line 48:
| Gleevec/Glivec
| Gleevec/Glivec
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| ALL, [[CML]]
| tyrosine kinase inhibitor
| [[tyrosine kinase inhibitor]]
|-
|-
| non-proprietary name
| dasatinib
| Sprycel
| Sprycel
| 7513 Euros/month<ref name=spiegel8_8_11_124/>
| 7513 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| ALL, CML
| notes?
| [[tyrosine kinase inhibitor]]
|-
|-
| nilotinib
| nilotinib
| Tasigna
| Tasigna
| 5685 Euros/month<ref name=spiegel8_8_11_124/>
| 5685 Euros/month<ref name=spiegel8_8_11_124/>
| CML
| [[CML]]
| tyrosine kinase inhibitor
| [[tyrosine kinase inhibitor]]
|-
|-
| lapatinib
| lapatinib
Line 72: Line 72:
==See also==
==See also==
*[[Cancer]].
*[[Cancer]].
*[[Neoadjuvant therapy]].


==References==
==References==

Latest revision as of 15:51, 18 March 2018

This article covers cancer drugs from a pathology perspective.

Drugs in a table

Non-proprietary name Trade name Cost Indication Notes
cetuximab Erbitux 5267 Euros/month[1] stomach cancer, head & neck cancer notes?
trastuzumab Herceptin 3345 Euros/month[1] breast cancer, stomach cancer notes?
gefitinib Iressa 3496 Euros/month[1] lung cancer EGFR inhibitor - like erlotinib
panitumumab Vectibix 3537 Euros/month[1] indication ??? notes?
fulvestrant Faslodex 719 Euros/month[1] breast cancer selective estrogen receptor down-regulator (SERD)
letrozole Femara 4189 Euros/month[1] indication ??? non-steroidal aromatase inhibitor
imatinib Gleevec/Glivec 4189 Euros/month[1] ALL, CML tyrosine kinase inhibitor
dasatinib Sprycel 7513 Euros/month[1] ALL, CML tyrosine kinase inhibitor
nilotinib Tasigna 5685 Euros/month[1] CML tyrosine kinase inhibitor
lapatinib Tyverb 3441 Euros/month[1] breast cancer tyrosine kinase inhibitor / HER2 growth receptor pathway blockade

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Grill, Markus; Hackenbroch, Veronika (2011), "[Medizin: Das grosse Versprechen]", Der Spiegel (32): 124-128, 8.8.2011